Recipients of hematopoietic stem cell transplantation
Conditions
Interventions
We measure titer of antibody against measles, mumps, rubella and VZV before vaccination. Administer live attenuated vaccine if patient'
s titer of antibody against virus is not positive. Second dose is administered at 4 - 12 weeks after first dose. Finally we measure titer of antibody of virus that vaccine was administered 8 - 16 week
Sponsors
Fukkuoka Blood and Marrow Transplantation Group
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients undergoing HSCT. 2. Twenty four months have been passed after HSCT. 3. No active chronic GVHD. 4. No immunosuppressive drugs such as tacrolimus, cyclosporine and prednisolone. 5. Three months have been passed after transfusion and six months after IVIG. 6. Patient's value go IVIG is equal or greater than 500 mg/dl. 7. Voluntary written informed consent.
Exclusion criteria
Exclusion criteria: 1. Patient who received immunosuppressive medications. 2. History of malignant tumors. 3. Severe uncontrolled psychiatric disorder or illness. 4. Serious concurrent uncontrolled medical disorders (hepatic dysfunction, renal failure, cardiac dysfunction, pulmonary dysfunction, diabetes, hypertension and infectious diseases). 5. Pregnant or lactating female. 6. Unwillingness or inability to follow the procedures required in the protocol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Titers of antibody against measles, rubella, mumps and VZV in HSCT patients after vaacination | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety of live attenuated vaccine in HSCT patients | — |
Countries
Japan
Contacts
Public ContactTomohiko Kamimura
Harasanshin General Hospital Department of Hematology
Outcome results
None listed